[May 19, 2016] |
|
True North Therapeutics to Present Clinical Data in Patients with Cold Agglutinin Disease (CAD) for Lead Product Candidate TNT009
True North Therapeutics, a clinical stage biotechnology company
developing novel therapies that selectively inhibit the Complement
system to treat rare diseases, today announced that a late-breaking
abstract describing clinical data from its ongoing Phase 1b clinical
study of TNT009 in patients with Cold Agglutinin Disease (CAD) has been
selected for presentation at the 21st Congress of the
European Hematology Association (EHA) held June 9-12, 2016 in
Copenhagen. The abstract describes clinical data related to the
Company's lead product candidate, TNT009, a first-in-class monoclonal
antibody that selectively inhibits the Classical Complement pathway by
targeting C1s, a serine protease within the C1-complex in the Complement
pathway of the immune system.
"We are excited to share these data demonstrating the robust activity of
TNT009 in patients with Cold Agglutinin Disease," said Nancy Stagliano,
PhD, Chief Executive Officer of True North. "True North is committed to
the accelerated development of a new therapeutic for patients who suffer
from this rare form of autoimmune hemolytic anemia."
|
|
|
|
|
Oral Presentation:
|
|
|
|
|
|
|
|
|
|
Title:
|
|
|
|
The Anti C1S Complement Antibody TNT009 Induces Rapid Complete
Remissions of Anaemia in Patients with Primary Cold Agglutinin
Disease
|
|
|
|
|
|
Author:
|
|
|
|
Jäger, Medical University of Vienna
|
|
|
|
|
|
Abstract:
|
|
|
|
LB2237
|
|
|
|
|
|
Late Breaking Session:
|
|
|
|
Topic: 26. Red blood cells and iron - Clinical
|
|
|
|
|
|
Date/Time:
|
|
|
|
Sunday, June 12, 2016, 12:15 - 12:30 CET
|
|
|
|
|
|
Location:
|
|
|
|
Hall A1
|
|
|
|
|
|
About Cold Agglutinin Disease (CAD) CAD is an autoimmune
hemolytic anemia in which autoantibodies target and destroy red blood
cells, causing anemia, fatigue and potentially fatal thrombosis. The
prevalence of primary CAD is approximately twenty per million. There are
limited treatment options available and many of these patients, despite
therapy, have moderate to severe anemia. True North sponsors a patient
registry for CAD and other autoimmune hemolytic anemias, called the
COMPASS Registry (https://www.compassregistry.org/),
dedicated to advancing a deeper understanding of these diseases,
engaging with patients, and supporting clinical trial recruitment.
About TNT009 TNT009 is a first-in-class monoclonal antibody
that selectively inhibits the Classical Complement pathway by targeting
C1s, a serine protease within the C1-complex in the Complement pathway
of the immune system. TNT009 thereby prevents downstream disease
processes involving phagocytosis, inflammation, and cell lysis. With a
unique mechanism of action and high target specificity, TNT009
selectively inhibits disease processes in the Classical Complement
pathway while maintaining the important immune surveillance provided by
the Alternative Complement Pathway and Lectin Complement Pathway. TNT009
is currently in clinical development for the treatment of Cold
Agglutinin Disease (CAD), a rare disease in hematology. Because numerous
other diseases are known to share the basic underlying mechanism
addressed by TNT009, the potential for other indications is clear.
About True North Therapeutics True North Therapeutics is a
clinical stage biotechnology company developing a pipeline of novel
therapies that selectively target the Complement pathway of the immune
system to address fundamental mechanisms in rare diseases with high
unmet need. The company's lead drug candidate, TNT009, offers a novel
approach for treating Complement-mediated diseases by selectively
inhibiting a target in the Classical Complement pathway. True North's
antibody drug development is focused on the treatment of rare diseases
mediated by the Complement system in hematology, transplantation, and
dermatology. True North Therapeutics is located in South San Francisco,
California. For more information, please visit www.truenorthrx.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160519005674/en/
[ Back To TMCnet.com's Homepage ]
|